Eric St-Amour
Impact in
-
- Diabetes Treatment and Management
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Diabetes Management and Research
- Nephrology top 2%
- Chronic Kidney Disease and Diabetes
Papers in
-
- Chronic Kidney Disease and Diabetes 4
- Dialysis and Renal Disease Management 1
-
- Diabetes Treatment and Management 5
- Journals
- The Lancet (4 papers)European Heart Journal (1 paper)Respiratory Research (1 paper)Kidney International (1 paper)JAMA Cardiology (1 paper)
- Partner nations
- United StatesAustraliaUnited Kingdom
In The Last Decade
Eric St-Amour
8 papers receiving 3.6k citations
Eric St-Amour's Hit Papers
Peers
Comparison fields: 5 of 80
- Endocrinology, Diabetes and Metabolism 2.6k
- Nephrology 575
- Cardiology and Cardiovascular Medicine 357
- Pharmacology 207
- Transplantation 23
Countries citing papers authored by Eric St-Amour
This map shows the geographic impact of Eric St-Amour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric St-Amour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric St-Amour more than expected).
Fields of papers citing papers by Eric St-Amour
This network shows the impact of papers produced by Eric St-Amour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric St-Amour. The network helps show where Eric St-Amour may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Hit paper breakdown → | 2019 | 2345 |
| 2 | Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial Hit paper breakdown → | 2021 | 546 |
| 3 | Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial Hit paper breakdown → | 2019 | 498 |
| 4 | 2021 | 100 | |
| 5 | 2021 | 91 | |
| 6 | 2018 | 72 | |
| 7 | 2021 | 71 | |
| 8 | 2020 | 60 |
About Eric St-Amour
Eric St-Amour is a scholar working on Nephrology, Endocrinology, Diabetes and Metabolism, Pharmacology, Oncology and Pulmonary and Respiratory Medicine, having authored 8 papers that have together received 3.8k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (5 papers), Chronic Kidney Disease and Diabetes (4 papers), Pharmacology and Obesity Treatment (1 paper), Inflammatory Biomarkers in Disease Prognosis (1 paper), Chronic Obstructive Pulmonary Disease (COPD) Research (1 paper) and Dialysis and Renal Disease Management (1 paper). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (2.6k citations), Nephrology (575 citations), Cardiology and Cardiovascular Medicine (357 citations), Pharmacology (207 citations) and Transplantation (23 citations). Eric St-Amour has collaborated with scholars based in United States, Australia and United Kingdom. Their work appears in journals such as The Lancet, European Heart Journal, Respiratory Research, Kidney International and JAMA Cardiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.